AIM: The financial burden of the increasing dialysis population challenges healthcare resources internationally. Home haemodialysis offers many benefits over conventional facility dialysis including superior clinical, patient-centred outcomes and reduced cost. This review updates a previous review, conducted a decade prior, incorporating contemporary home dialysis techniques of frequent and nocturnal dialysis. We sought comparative cost-effectiveness studies of home versus facility haemodialysis (HD) for people with end-stage kidney failure (ESKF). METHODS: We conducted a systematic review of literature from January 2000-March 2014. Studies were included if they provided comparative information on the costs, health outcomes and cost-effectiveness ratios of home HD and facility HD. We searched medical and health economic databases using MeSH headings and text words for economic evaluation and haemodialysis. RESULTS: Six studies of economic evaluations that compared home to facility HD were identified. Two studies compared home nocturnal HD, one home nocturnal and daily home HD, and three compared contemporary home HD to facility HD. Overall these studies suggest that contemporary home HD modalities are less costly and more effective than facility HD. Home HD start-up costs tend to be higher in the short term, but these are offset by cost savings over the longer term. CONCLUSIONS: Contemporaneous dialysis modalities including nocturnal and daily home haemodialysis are cost-effective or cost-saving compared with facility-based haemodialysis. This result is largely driven by lower staff costs, and better health outcomes for survival and quality of life. Expanding the proportion of haemodialysis patients managed at home is likely to produce cost savings.
AIM: The financial burden of the increasing dialysis population challenges healthcare resources internationally. Home haemodialysis offers many benefits over conventional facility dialysis including superior clinical, patient-centred outcomes and reduced cost. This review updates a previous review, conducted a decade prior, incorporating contemporary home dialysis techniques of frequent and nocturnal dialysis. We sought comparative cost-effectiveness studies of home versus facility haemodialysis (HD) for people with end-stage kidney failure (ESKF). METHODS: We conducted a systematic review of literature from January 2000-March 2014. Studies were included if they provided comparative information on the costs, health outcomes and cost-effectiveness ratios of home HD and facility HD. We searched medical and health economic databases using MeSH headings and text words for economic evaluation and haemodialysis. RESULTS: Six studies of economic evaluations that compared home to facility HD were identified. Two studies compared home nocturnal HD, one home nocturnal and daily home HD, and three compared contemporary home HD to facility HD. Overall these studies suggest that contemporary home HD modalities are less costly and more effective than facility HD. Home HD start-up costs tend to be higher in the short term, but these are offset by cost savings over the longer term. CONCLUSIONS: Contemporaneous dialysis modalities including nocturnal and daily home haemodialysis are cost-effective or cost-saving compared with facility-based haemodialysis. This result is largely driven by lower staff costs, and better health outcomes for survival and quality of life. Expanding the proportion of haemodialysis patients managed at home is likely to produce cost savings.
Authors: Oanh Kieu Nguyen; Miguel A Vazquez; Lakeesha Charles; Joseph R Berger; Henry Quiñones; Richard Fuquay; Joanne M Sanders; Kandice A Kapinos; Ethan A Halm; Anil N Makam Journal: JAMA Intern Med Date: 2019-02-01 Impact factor: 21.873
Authors: Annie-Claire Nadeau-Fredette; Carmel M Hawley; Elaine M Pascoe; Christopher T Chan; Philip A Clayton; Kevan R Polkinghorne; Neil Boudville; Martine Leblanc; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2015-06-11 Impact factor: 8.237
Authors: Rachael C Walker; Rachael L Morton; Suetonia C Palmer; Mark R Marshall; Allison Tong; Kirsten Howard Journal: Clin J Am Soc Nephrol Date: 2017-10-19 Impact factor: 8.237
Authors: Rebecca Kurnik Seshasai; Nandita Mitra; C Michael Chaknos; Jiaqi Li; Christopher Wirtalla; Dan Negoianu; Joel D Glickman; Laura M Dember Journal: Am J Kidney Dis Date: 2015-12-18 Impact factor: 8.860
Authors: Adam S Wilk; Richard A Hirth; Wei Zhang; John R C Wheeler; Marc N Turenne; Tammie A Nahra; Kathryn K Sleeman; Joseph M Messana Journal: Health Serv Res Date: 2017-01-19 Impact factor: 3.734
Authors: Rachael C Walker; Rachael L Morton; Allison Tong; Mark R Marshall; Suetonia Palmer; Kirsten Howard Journal: BMJ Open Date: 2015-04-15 Impact factor: 2.692
Authors: Thomas W Ferguson; James Zacharias; Simon R Walker; David Collister; Claudio Rigatto; Navdeep Tangri; Paul Komenda Journal: PLoS One Date: 2015-08-18 Impact factor: 3.240